GlassScriptPhysician profile
Douglas Wisor
NPI 1902874449
$2,754.86
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $1,429 · 2021: $551 · 2022: $246.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,228.85 | 2019-2020 | |
| Medtronic USA, INC. | $473.97 | 2019-2020 | |
| Medtronic, INC. | $244.81 | 2021 | |
| Vertos Medical, INC. | $180.73 | 2021 | |
| Nevro Corp. | $140.49 | 2019-2022 | |
| Nalu Medical, INC. | $129.87 | 2022 | |
| Pacira Therapeutics, INC. | $122.82 | 2019 | |
| Stimwave Technologies Incorporated | $100.62 | 2021 | |
| Boston Scientific Corporation | $73.73 | 2019 | |
| Novartis Pharmaceuticals Corporation | $40.50 | 2019-2021 | |
| Fidia Pharma USA INC. | $18.47 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Wisor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.